Diagnostic Utility of Genome-wide DNA Methylation Analysis in Genetically Unsolved Developmental and Epileptic Encephalopathies and Refinement of a CHD2 Episignature
Christy W LaFlamme,Cassandra Rastin,Soham Sengupta,Helen E Pennington,Sophie J Russ-Hall,Amy L Schneider,Emily S Bonkowski,Edith P Almanza Fuerte,Miranda Galey,Joy Goffena,Sophia B Gibson,Talia J Allan,Denis M Nyaga,Nico Lieffering,Malavika Hebbar,Emily V Walker,Daniel Darnell,Scott R Olsen,Pandurang Kolekar,Nahdir Djekidel,Wojciech Rosikiewicz,Haley McConkey,Jennifer Kerkhof,Michael A Levy,Raissa Relator,Dorit Lev,Tally Lerman-Sagie,Kristen L Park,Marielle Alders,Gerarda Cappuccio,Nicolas Chatron,Leigh Demain,David Genevieve,Gaetan Lesca,Tony Roscioli,Damien Sanlaville,Matthew L Tedder,Monika Weisz Hubshman,Shamika Ketkar,Hongzheng Dai,Kim Carlyle Worley,Jill A Rosenfeld,Hsiao-Tuan Chao,Undiagnosed Diseases Network,Geoffrey Neale,Gemma L Carvill,University of Washington Center for Rare Disease Research,Zhaoming Wang,Samuel F Berkovic,Lynette G Sadleir,Danny E Miller,Ingrid E Scheffer,Bekim Sadikovic,Heather C Mefford
DOI: https://doi.org/10.1101/2023.10.11.23296741
2023-10-12
MedRxiv
Abstract:Sequence-based genetic testing currently identifies causative genetic variants in ∼50% of individuals with developmental and epileptic encephalopathies (DEEs). Aberrant changes in DNA methylation are implicated in various neurodevelopmental disorders but remain unstudied in DEEs. Rare epigenetic variations ("epivariants") can drive disease by modulating gene expression at single loci, whereas genome-wide DNA methylation changes can result in distinct "episignature" biomarkers for monogenic disorders in a growing number of rare diseases. Here, we interrogate the diagnostic utility of genome-wide DNA methylation array analysis on peripheral blood samples from 516 individuals with genetically unsolved DEEs who had previously undergone extensive genetic testing. We identified rare differentially methylated regions (DMRs) and explanatory episignatures to discover causative and candidate genetic etiologies in 10 individuals. We then used long-read sequencing to identify DNA variants underlying rare DMRs, including one balanced translocation, three CG-rich repeat expansions, and two copy number variants. We also identify pathogenic sequence variants associated with episignatures; some had been missed by previous exome sequencing. Although most DEE genes lack known episignatures, the increase in diagnostic yield for DNA methylation analysis in DEEs is comparable to the added yield of genome sequencing. Finally, we refine an episignature for CHD2 using an 850K methylation array which was further refined at higher CpG resolution using bisulfite sequencing to investigate potential insights into CHD2 pathophysiology. Our study demonstrates the diagnostic yield of genome-wide DNA methylation analysis to identify causal and candidate genetic causes as ∼2% (10/516) for unsolved DEE cases.